Josep Sanfeliu
Managing Partner and Co-Founder @ Asabys Partners
Barcelona, Spain
Josep Sanfeliu is a Series B investor at Asabys Partners in Barcelona focused on Medical Device and Medical. Josep Ll. Sanfeliu is based out of Barcelona, Catalonia and is the Board of Directors of SafeHeal. Josep previously worked at Anaconda BioMed as a Board Director as an Asabys Partners investment. Josep Ll. Sanfeliu attended the University of Michigan Law School.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 62%
Last updated:
For AI agents: llms.txt
Industries Josep Sanfeliu invests in
Stages Josep Sanfeliu invests in
Countries Josep Sanfeliu invests in
Round sizes
Round size
- Series A
- $20M–$20M
- Series B
- $18M–$55M
- Series C
- $12M–$57M
Investment Focus
Industry
- Medical Device 6 (46%)
- Medical 5 (38%)
- Health Care 5 (38%)
- Biotechnology 2 (15%)
- Artificial Intelligence 2 (15%)
Stage
- Series B 4 (31%)
- Series C 3 (23%)
- Series A 2 (15%)
- Seed 1 (8%)
- Pre-Seed 1 (8%)
Country
- Spain 4 (31%)
- France 1 (8%)
- Israel 1 (8%)
- Iceland 1 (8%)
- United States 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SafeHeal
|
SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) andof the iLab grant program, which foster talent and bring out future champions of the French economy.SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition.Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people. | $11.7M / Series C / Sep 10, 2025 | |
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
INBRAIN Neuroelectronics
|
INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $49.8M / Series B / Oct 29, 2024 | |
|
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $18.1M / Series B / Mar 01, 2023 | |
Sidekick Health
|
Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare.The Sidekick platform combines an evidence-based clinical approachwith behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences.Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first. | $55M / Series B / May 05, 2022 | |
|
INBRAIN Neuroelectronics
|
INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $19.8M / Series A / Mar 26, 2021 | |
|
Sidekick Health
|
Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare.The Sidekick platform combines an evidence-based clinical approachwith behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences.Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first. | $20M / Series A / Oct 28, 2020 | |
Medasense
|
Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedicationMedasense’s flagship product, the PMD-200 with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of artificial intelligence and aproprietary non-invasive sensor platform. The PMD-200 is used to optimize pain management in operating rooms and critical care settings, where patients are unable to communicate – a $5B market. The company’s pipeline cloud-based solutions for clinics and home, leveraging the NOL technology, addresses an additional $15B global market.The PMD-200 is distributed in Europe exclusively by Medtronic (NYSE:MDT), is cleared for marketing also in Canada, Latin America and Australia, and enables connectivity with Philips patient monitors. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid-sparing.Medasense was founded in 2008 and based in Ramat Gan, Tel Aviv, Israel. | $18M / Series C / Sep 22, 2020 | |
|
INBRAIN Neuroelectronics
|
INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and strokerehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn. | $1.3M / Seed / Jun 11, 2020 | |
Anaconda BioMed
|
Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS). | $21.9M / Series B / Dec 04, 2019 | |
| See all 13 investments → | |||
Co-Investors
About Asabys Partners
Asabys Partners is a venture capital firm that invests across the board in human healthcare. The company is active in the health-tech and biopharma industries and aims to invest in Spain and abroad in innovative and transformative technologies. Asabys Partners are motivated by the idea of pushing the boundaries of science and medicine. This is donethrough the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry.
Asabys Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Clara Campas Moya
Managing Partner and co-founder
|
|||
Montserrat Vendrell
Partner
|
|||
Nuria Aloy
CFO
|
|||
|
Josep Sanfeliu
Managing Partner and Co-Founder
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Josep Sanfeliu invest in?
Josep Sanfeliu invests primarily in Medical Device, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 13 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Josep Sanfeliu's check size?
Josep Sanfeliu typically joins rounds of $20M–$20M at Series A, $18M–$55M at Series B and $12M–$57M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Josep Sanfeliu participates in.
When did Josep Sanfeliu last invest?
The most recent investment recorded for Josep Sanfeliu closed in Sep 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
